Document is current
Any future updates will be listed below
-
Authors
Mills, Matthew N.
Thawani, Chetna
Figura, Nicholas B.
Oliver, Daniel E.
Soyano, Aixa E.
Etame, Arnold
Robinson, Timothy J.
Liu, James K.
Vogelbaum, Michael A.
Forsyth, Peter A.
Czerniecki, Brian J.
Soliman, Hatem H.
Han, Hyo S.
Yu, Hsiang-Hsuan Michael
Ahmed, Kamran A. https://orcid.org/0000-0003-3331-1529
- License Information
-
More Information
Article History
Received: 27 January 2021
Accepted: 9 March 2021
First Online: 19 March 2021
Declarations
:
: Hsiang-Hsuan Michael Yu has received speaker’s honoraria from BrainLab and is on the advisory boards of Novocure and Abbvie. Michael A. Vogelbaum has indirect equity and royalty interests in Infuseon Therapeutics, Inc. and has received honoraria from Tocagen, Inc. and Celgene. Peter A. Forsyth has received research funding from Pfizer and Celgene and is on the advisory boards of Novocure, BTG, Inovio, AbbVie, Ziopharm, Tocagen, and Pfizer. Hatem Soliman serves as a consultant for Astrazeneca, Celgene, Novartis, PUMA, and Eisai. Brian J Czerniecki has intellectual property on a HER2 dendritic cell vaccine. Hyo S. Han declares that she has received a speaker’s honorarium from Lilly Pharmaceuticals, research funding from Abbvie, Arvinas, GSK, Marker therapeutic, Novartis, Bristol-Myers Squibb, Pfizer, SeattleGenetics, Prescient, Horizon, Zymeworks and Karyopharm. Kamran A. Ahmed has received research funding from Bristol-Myers Squibb, Eli Lilly, and Genentech.
: This study was approved by the University of South Florida Institutional Review Board.
